Co-Founder and CTO of numerous MEMS-based companies, including Cepheid and SiTime. Kurt was recently awarded the IEEE Medal of Honor for his contribution to the field of MEMS. Cardean Transistors are very similar to MEMS in many regards and Kurt’s experience with MEMS as it applies to biotechnology will elevate Cardea’s chip designs and capabilities.
One of the first to discover and characterize the CRISPR-Cas9 complex and recognize its potential in biochemical applications. Since CRISPR-Chip is an important pillar for Cardea, enabling nucleic acid detection, his expertise regarding the CRISPR complex will be important as Cardea expands the capabilities of the technology.
A visionary in bringing the most advanced forms of data management and analytics to healthcare. Dr. Stupka’s work has contributed to the understanding of the human genome, transcriptome, and the development of gene-therapeutics. His understanding of data and its role in enhancing the value of any technology will help steer Cardea’s data management capabilities adding value to every Innovation Partner application.
A Fellow of the American College of Medical Genetics and Genomics and founder and Principal of ResearchDx. Dr. Cotter has been a leader in developing sequencing as a clinical diagnostics tool as the director of Illumina Clinical Services Laboratory, and through ResearchDx is a leader in the development of companion diagnostics.
Doctor and researcher at Rady Children’s Genomic Institute, with expertise in genetic disorders, infectious disease detection, and nucleic acid-based diagnostics. Dr. Farnaes has pioneered the use of Rapid Whole Genome Sequencing to diagnose rare genetic disorders in children. His insight into developing diagnostics with clear medical relevance will be important for Cardea’s medical Innovation Partners.
Distinguished Professor of Genetics and the Neil and Rochelle Campbell Chair for Innovation in Science Education at the University of California Riverside. In 2011 she was elected Home Secretary of the U.S. National Academy of Sciences (NAS), the first woman to hold this position in its 150-year history. She is a plant molecular geneticist known for her contributions to the field of transposon biology and plant genome evolution.
Ken Hood is the Managing Partner of FusionX Ventures, a fund focused on helping companies build the next generation of cloud-enabled Smart Machines and instruments. Ken has been the co-founder and CEO of more companies.
Tim Hoerr is the CEO & Managing Partner of Serra Ventures, that was the lead investor of the in A round. Before starting the VC fund Tim was the co-founder and CEO of iCyt Mission Technology, a bio-instrument company, which was sold to Sony in 2009.
Serves as both Chairman of the Innovation Council and Chairman of the Board of Directors of Cardea. Paul brings extensive experience from multiple biotech CEO positions and from having been on the Illumina board for 2005-2013, from the early days to Illumina being a global business. Paul was a Medical Doctor before going into drug R&D and later biotech business.
Rob and his team are responsible for the Innovation Partnership Program (IPP) at Cardea.
In the past decade alone, Rob served as Thermo Fisher’s Director of Business Development and Americas Marketing, and as Senior Vice President of Commercial Operations at Sequenom, a groundbreaker in genomic testing in the now rapidly growing noninvasive prenatal testing market. In 2016, Sequenom was successfully transacted to LabCorp. Most recently, Rob was President of Specific Diagnostics, a private Silicon Valley based company focused on microbiology.